Patents Examined by Suzanne E. Ziska
  • Patent number: 11913022
    Abstract: Human induced pluripotent stem cells (iPSCs) can give rise to multiple cell types and hold great promise in regenerative medicine and disease modeling applications. The Inventors herein developed a reliable two-step protocol to generate human mammary-like organoids from iPSCs. Non-neural ectoderm cell-containing spheres, referred to as mEBs, were first differentiated and enriched from iPSCs using MammoCult medium. Gene expression profile analysis suggested that mammary gland function-associated signaling pathways were hallmarks of 10-d differentiated mEBs. The Inventors generated mammary-like organoids from 10-d mEBs using 3D floating mixed gel culture and a three-stage differentiation procedure. These organoids expressed common breast tissue, luminal, and basal markers, including estrogen receptor, and could be induced to produce milk protein. These results demonstrate that human iPSCs can be directed in vitro toward mammary lineage differentiation.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: February 27, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Ying Qu, Xiaojiang Cui, Dhruv Sareen, Armando E. Giuliano
  • Patent number: 11884935
    Abstract: The present invention relates to a method for inducing trans-differentiation of cardiomyocytes based on exosome, and more particularly, to a method for inducing trans-differentiation of a fibroblast into a cardiomyocyte, comprising the steps of: isolating exosomes in a culture medium during a process of differentiating a stem cell into the cardiomyocyte; culturing a fibroblast in a cardiomyocyte reprogramming medium containing the isolated exosomes; and culturing the fibroblast cultured in a cardiomyocyte differentiation medium containing the isolated exosomes.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: January 30, 2024
    Inventors: Ick Chan Kwon, Sun Hwa Kim, Yoosoo Yang, Hyosuk Kim
  • Patent number: 11859204
    Abstract: A mold for producing a hydrogel support for a 3-dimensional (3D) cell culture, includes: an upper mold comprising a base and a plurality of upper unit molds protruding downward from the base to form accommodating portions of a female type corresponding to shapes of hydrogel supports, having through holes at bottoms thereof, and patterned at a lower portion of the base; a lower mold where a plurality of lower unit molds are patterned, the plurality of lower unit molds formed in a female type to respectively accommodate the plurality of upper unit molds protruding downward and having sealed lower portions; and an ejecting unit for separating, from the accommodating portions of the plurality of upper unit molds, the hydrogel supports that are coagulated after being inserted into the through holes respectively formed in the plurality of upper unit molds.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: January 2, 2024
    Inventors: Sik Yoon, Ye Seon Lim, Ye Jin Ok, Sun Young Hwang, Kang Oh Lee, Seung Soo Lee
  • Patent number: 11851677
    Abstract: Compositions and methods for manufacturing induced immune regulatory cells comprising induced myeloid suppressive cells including MDSCs (myeloid-derived suppressor cells), dendritic cells, macrophages, and subpopulations thereof are provided. Also provided are methods and compositions for further modifying and modulating the induced immune regulatory cells to achieve enhanced therapeutic potential in treating autoimmune disorders, hematological malignancies, solid tumors, viral infections, neurodegenerative disorders, inflammatory conditions, or GvHD.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: December 26, 2023
    Inventors: Philippe A. Parone, Robert S. Tacke, Bahram Valamehr, Daniel Shoemaker, Martin Hosking, Lisa Guerrettaz
  • Patent number: 11849719
    Abstract: The present disclosure relates to an improved process of organ perfusion with vitrifiable concentrations of cryoprotective agents. In one implementation, the method may include perfusing an organ with a first solution containing a vitrifiable concentration of cryoprotectant at a temperature at or above ?10° C. and perfusing the organ with a second solution containing a higher concentration of cryoprotectant than the first solution. The first solution may be adapted to vitrify at a cooling rate of less than 20° C./min, and the second solution may be adapted to vitrify at a cooling rate of less than 5° C./min. The perfusing with the second solution may begin at or above ?10° C. and cause the organ to decline in temperature to below ?10° C.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: December 26, 2023
    Assignee: 21st Century Medicine, Inc.
    Inventor: Gregory M. Fahy
  • Patent number: 11807870
    Abstract: The invention relates to a cellular microcompartment comprising successively, organized around a lumen, at least one layer of pluripotent cells, an extracellular matrix layer and an outer hydrogel layer. The invention also relates to processes for preparing such cellular microcompartments.
    Type: Grant
    Filed: November 23, 2017
    Date of Patent: November 7, 2023
    Inventors: Maxime Feyeux, Kevin Alessandri, Pierre Nassoy, Laurent Cognet, Gaëlle Recher, Erwan Bezard
  • Patent number: 11730165
    Abstract: An organ container includes a bottomed tubular outer container and a bottomed tubular inner container that is fitted into the outer container. A fluid flow path is formed between an outer peripheral surface of the inner container and an inner peripheral surface of the outer container. The outer container has an inlet that communicates between the fluid flow path and the outside, and an outlet that communicates between the fluid flow path and the outside.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: August 22, 2023
    Inventors: Shinji Torai, Hiroo Kasamatsu, Syuhei Yoshimoto
  • Patent number: 11624056
    Abstract: The present invention relates to a method for inducing differentiation, into chondrocytes, of cord blood mononuclear cell-derived induced pluripotent stem cells. In a case where a chondrogenic pellet produced by the method of the present invention is transplanted into a cartilage damage area in vivo, regeneration of cartilage can be effectively exhibited by differentiated chondrocytes. In such a case, an effective cartilage regeneration capacity can be exhibited as compared with a case where chondrocytes produced by differentiation induction with the addition of a recombinant growth factor are transplanted. Thus, the present invention can be usefully used for tissue engineering therapies.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: April 11, 2023
    Assignee: YiPCELL Inc.
    Inventors: Ji Hyeon Ju, Yoo Jun Nam, Yeri Rim
  • Patent number: 11572544
    Abstract: Embodiments herein relate to in vitro production methods of hematopoietic stem cell (HSC) and hematopoietic stem and progenitor cell (HSPC) that have long-term multilineage hematopoiesis potentials upon in vivo engraftment. The HSC and HSPCs are derived from pluripotent stem cells-derived hemogenic endothelia cells (HE) by non-integrative episomal vectors-based gene transfer.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: February 7, 2023
    Inventor: George Q. Daley
  • Patent number: 11512273
    Abstract: Disclosed is an apparatus for the production of tissue from cells. The apparatus comprises an elongate body having at least one circumferential groove and being operable to extend, by close-fitting relationship, centrally through at least one trough. The troughs are extending in a closed path, such that the at least one of the circumferential grooves open into an inner edge of a trough. Also disclosed is a process for production of tissue from cells, via a transitioning intermediate which transitions from the cells into the tissue.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: November 29, 2022
    Assignee: MOSA MEAT B.V.
    Inventors: Jonathan Jan Breemhaar, Mark Post
  • Patent number: 6051396
    Abstract: A method that produces substantial quantities of a desired polypeptide, by delivering genetic material into insect cells. For example, cloned genes, or gene fragments or, derivates may be defined, utilizing as appropriate vector, into host cells for high level production of high purity protein in substantial quantities.
    Type: Grant
    Filed: May 7, 1993
    Date of Patent: April 18, 2000
    Assignee: The Regents of the University of California
    Inventors: Wen-Hwa Lee, Eva Y.-H. P. Lee
  • Patent number: 6020153
    Abstract: The invention relates to murine/human chimeric monoclonal antibodies with high specificity to and affinity for human carcinoembryonic antigen (CEA), derivatives thereof, processes for the preparation of these antibodies and their derivatives, DNAs coding for heavy and light chains of these antibodies, processes for the preparation of said DNAs, mammalian cell lines that produce and secrete the antibodies and processes for the preparation of said cell lines. The chimeric antibodies and their derivatives are used for clinical purposes in vitro and in vivo, especially for the diagnosis of cancer, for localization and in vivo imaging of tumors, for therapy, e.g. site-directed delivery of cytotoxins, and similar purposes. The invention also concerns test kits and pharmaceutical compositions containing said chimeric monoclonal antibodies and/or derivatives thereof.
    Type: Grant
    Filed: September 16, 1994
    Date of Patent: February 1, 2000
    Assignee: Ciba-Geigy Corporation
    Inventors: Norman Hardman, Laura Lee Gill, Ronald F. J. de Winter, Kathrin Wagner, Christoph Heusser
  • Patent number: 5902880
    Abstract: A transcribed non-naturally occuring RNA molecule comprising a desired RNA molecule, wherein the 3' region of the RNA is able to base-pair with at least 8 bases at the 5' terminus of the same RNA molecule.
    Type: Grant
    Filed: November 10, 1994
    Date of Patent: May 11, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventor: James Thompson
  • Patent number: 5891693
    Abstract: The present invention relates to vectors useful for transforming a lymphoid cell line to glutamine independence. The vectors comprise an active glutamine synthetase (GS) gene as well as a heterologous gene of interest to be expressed. The preferred embodiments encompass vectors wherein the heterologous gene is expressed from a relatively strong promoter and the GS gene is expressed from a relatively weak promoter. In one example, the heterologous gene is operatively linked to the hCMV-MIE promoter and the GS gene is operatively linked to the SV40 early region promoter.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: April 6, 1999
    Assignee: Alusuisse Holdings A.G.
    Inventors: Christopher Robert Bebbington, Geoffrey Thomas Yarranton, Richard H. Wilson
  • Patent number: 5885795
    Abstract: The present invention comprises an endothelial inhibitor and method of use therefor. The endothelial inhibitor is a protein isolated from the blood or urine that is eluted as a single peak from C4-reverse phase high performance liquid chromatography. The endothelial inhibitor is a molecule comprising a protein having a molecular weight of between approximately 38 kilodaltons and 45 kilodaltons as determined by reducing polyacrylamide gel electrophoresis and having an amino acid sequence substantially similar to that of a murine plasminogen fragment beginning at amino acid number 98 of a murine plasminogen molecule.
    Type: Grant
    Filed: April 26, 1995
    Date of Patent: March 23, 1999
    Assignee: The Children's Medical Center Corporation
    Inventors: Michael S. O'Reilly, M. Judah Folkman, Kim Lee Sim
  • Patent number: 5880274
    Abstract: A Gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglobulin .lambda. chain; a gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglobulin .kappa. chain; a gene fragment which comprises a DNA sequence coding for the constant region of feline immunoglobulin .gamma.
    Type: Grant
    Filed: November 17, 1995
    Date of Patent: March 9, 1999
    Assignee: Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute
    Inventors: Hiroaki Maeda, Yasuyuki Eda, Kazuhiko Kimachi, Yoichi Ono, Sachio Tokiyoshi
  • Patent number: 5877397
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and transgenic non-human animals having inactivated endogenous immunoglobulin genes. In one aspect of the invention, endogenous immunoglobulin genes are suppressed by antisense polynucleotides and/or by antiserum directed against endogenous immunoglobulins. Heterologous antibodies are encoded by immunoglobulin genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, one or more transgenes containing sequences of unrearranged heterologous human immunoglobulin heavy chains are introduced into a non-human animal thereby forming a transgenic animal capable of functionally rearranging transgenic immunoglobulin sequences and producing a repertoire of antibodies of various isotypes encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g.
    Type: Grant
    Filed: September 19, 1994
    Date of Patent: March 2, 1999
    Assignee: GenPharm International Inc.
    Inventors: Nils Lonberg, Robert M. Kay
  • Patent number: 5859312
    Abstract: The invention provides transgenic non-human animals and transgenic non-human mammalian cells having at least one functionally disrupted lymphocyte transduction locus, particularly a CD4 locus, targeting constructs used to produce such transgenic stem cells and animals, methods and targeting constructs for inactivating or suppressing expression of endogenous lymphocyte transduction gene loci, transgenes encoding heterologous lymphocyte transduction proteins, and nonhuman animals that express a human lymphocyte transduction protein and lack expression of a cognate murine lymphocyte transduction protein.
    Type: Grant
    Filed: July 8, 1996
    Date of Patent: January 12, 1999
    Assignee: The Regents of the University of California
    Inventors: Daniel Littman, Shinichiro Sawada, Nigel Killeen
  • Patent number: 5850002
    Abstract: Genetically engineered animals are described that have lost the expression of a homeobox gene and are missing an organ whose development is regulated by that homeobox gene. Such animals are models for organogenesis and can be used in methods for screening for compounds and gene therapies that restore the function of the missing organ. Other genetically engineered animals are described which express a homeobox gene in cells not normally expressing the gene and exhibit a developmental and/or pathologic condition in those cells. Such animals are models for gain of homeobox function and can be used in methods to screen for compounds and gene therapies that affect the developmental and/or pathologic condition due to the gain of homeobox gene expression.
    Type: Grant
    Filed: September 13, 1996
    Date of Patent: December 15, 1998
    Assignee: Washington University
    Inventor: Stanley J. Korsmeyer
  • Patent number: 5850001
    Abstract: The present invention relates to a transgenic non-human mammal, whose germ cells and somatic cells contain a recombinant env gene sequence which is operably linked to a promoter effective for the expression of the gene in the neuronal tissues of the mammal and effective for the simulation of neurological syndromes associated with HIV-1, the gene being introduced into the mammal, or an ancestor of the mammal, at an embryonic stage. The transgenic non-human mammal is such that transcription of the env gene may be under the control of a promoter sequence, such as a neuron specific promoter of human neurofilament heavy gene (NFH). The promoter can be synthetic or inducible. The transgenic non-human mammal can be a rodent, such as a mouse.
    Type: Grant
    Filed: July 24, 1996
    Date of Patent: December 15, 1998
    Assignee: Universite de Montreal
    Inventors: Allegria Kessous-Elbaz, Jean Michaud, Fouad Berrada